Tim Schlidt, a cofounder and partner at Palo Santo; Serebrinsky; and David Langer, a founding partner at Lionheart Venturesis a software platform that allows mental-health providers to administer psychedelics therapy, monitor patient outcomes, streamline workflows, and prescribe drugs. : Schlidt said that the company is a pioneer creating an electronic health record for ketamine clinics and has"rockstar founders.
"They have managed to bring reputable VC funds such as General Catalyst on board, which has lent additional validation and credibility to their platform," Schlidt said. Serebrinsky said that the data that Osmind collects could help treatments qualify for insurance coverage and may pave the way for safer and more effective treatments than ketamine, which can be addictive.
Langer said that Osmind is the only psychedelics startup to have a pre-seed round where Lionheart Ventures wanted to invest,"but the round moved too fast for us and we missed out."Alexander Volkov/Getty Images
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
7 companies that recently dropped college degree requirements for new hiresInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know. Equity... Of course so that when the downtime comes, you will be the first to be shown the beautiful exit door No company was mentioned in the article
مصدر: BusinessInsider - 🏆 729. / 51 اقرأ أكثر »